Pancreatic cancer is the fourth leading cause of cancer-related death in North America and is associated with an extremely bleak prognosis. Advances in the treatment of this devastating disease will require novel approaches. A key therapeutic strategy is inhibition of the epidermal growth factor receptor (EGFR). The EGFR is overexpressed in pancreatic cancer and is associated with poor prognosis. This article summarizes current knowledge of the role of EGFR antagonists in pancreatic cancer and focuses on the preclinical background and EGFR inhibitors in clinical development including erlotinib, gefitinib, cetuximab, and matuzumab.
American Journal of Cancer – Springer Journals
Published: Aug 9, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.